TRAX Stock Forecast: First Tracks Biotherapeutics, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering First Tracks Biotherapeutics, Inc. hold a median 12-month price target of $70 — +68.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores First Tracks Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (53): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TRAX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TRAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.1% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Guggenheim | Maintains | Buy | $100 → $110 |
| 16 Oct 2026 | Leerink Partners | Maintains | Outperform | $70 → $90 |
| 13 Oct 2026 | Canaccord Genuity | Maintains | Buy | $50 → $60 |
| 13 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $65 → $70 |
| 13 Oct 2026 | Wells Fargo | Maintains | Overweight | $62 → $70 |
| 30 Sept 2026 | Canaccord Genuity | Initiates | Buy | $50 |
| 18 Sept 2026 | Evercore ISI Group | Initiates | Outperform | $65 |
| 16 Sept 2026 | Guggenheim | Initiates | Buy | $100 |
| 3 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $57 |
| 13 Aug 2026 | Barclays | Maintains | Overweight | $48 → $65 |
| 13 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $44 → $57 |
| 13 Aug 2026 | Piper Sandler | Maintains | Overweight | $54 → $95 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $60 → $70 |
| 10 Aug 2026 | UBS | Maintains | Buy | $45 → $65 |
| 28 July 2026 | Wedbush | Maintains | Outperform | $30 → $60 |
| 28 July 2026 | Wells Fargo | Maintains | Overweight | $30 → $55 |
| 21 July 2026 | Barclays | Maintains | Overweight | $40 → $48 |
| 10 July 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $44 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $30 |
| 8 June 2026 | Wells Fargo | Initiates | Overweight | $30 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TRAX.
This page is one stock. Monday covers all of them.
TRAX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TRAX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TRAX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 9.9×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −41.8%
- Return on assets
- −37.0%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
First Tracks Biotherapeutics, Inc. has a market value of $1.7B and an enterprise value of $1.7B.
First Tracks Biotherapeutics, Inc. employs 104 people.
Data provided by Twelve Data
TRAX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TRAX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own First Tracks Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TRAX
What is the TRAX stock price forecast for 2026-2027?
The 12 Wall Street analysts covering First Tracks Biotherapeutics, Inc. have a median 12-month price target of $70, with estimates ranging from $57 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TRAX stock a buy right now?
Of the 12 analysts covering First Tracks Biotherapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks First Tracks Biotherapeutics, Inc. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TRAX?
As at 21 Nov 2026, First Tracks Biotherapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (53 of 100).
Will TRAX stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +68.1% from the last close, and Ticker Nerd's factor model ranks First Tracks Biotherapeutics, Inc. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TRAX stock forecast for 2030?
No analyst covering First Tracks Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $57 to $110 over the next 12 months.
What does First Tracks Biotherapeutics, Inc. do?
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company’s current pipeline centers on three antibody-based programs: rosnilimab, designed to selectively deplete pathogenic T cells; ANB033, an anti-CD122 antagonist being studied in immune-mediated conditions such as celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells.
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company’s current pipeline centers on three antibody-based programs: rosnilimab, designed to selectively deplete pathogenic T cells; ANB033, an anti-CD122 antagonist being studied in immune-mediated conditions such as celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. Its work is concentrated in research and development, with a focus on advancing therapies that address immune pathway dysfunction across rheumatology and gastroenterology settings. First Tracks Biotherapeutics, Inc. operates as a specialized player in the biotechnology market, contributing to the broader development of targeted treatments for complex inflammatory disorders.
CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.firsttracksbio.com